Nuwellis, Inc. (NASDAQ: NUWE) Stock Competitors & Peer Comparison
See NUWE's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NUWE and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NUWE | $4.45 | +135.45% | 1.6M | -1.95 | -$2.28 | N/A |
| ABT | $105.61 | -2.21% | 184B | 20.27 | $5.21 | +2.35% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $348.04 | -1.20% | 133.6B | 26.02 | $13.39 | +1.00% |
| ISRG | $352.97 | -2.44% | 124.7B | 36.70 | $9.62 | N/A |
| MDT | $85.71 | -2.09% | 109.7B | 15.50 | $5.53 | +3.32% |
| BSX | $46.00 | -0.09% | 68.4B | 14.84 | $3.10 | N/A |
| EW | $86.92 | +1.35% | 50.1B | 32.20 | $2.70 | N/A |
| RMD | $208.56 | -2.67% | 30.3B | 19.37 | $10.77 | +1.16% |
| DXCM | $74.54 | -0.80% | 28.8B | 31.99 | $2.33 | N/A |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
NUWE vs ABT Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, ABT has a market cap of 184B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while ABT trades at $105.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas ABT's P/E ratio is 20.27. In terms of profitability, NUWE's ROE is -170.16%, compared to ABT's ROE of +0.11%. Regarding short-term risk, NUWE is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
NUWE vs BSX-PA Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, NUWE's ROE is -170.16%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, NUWE is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
NUWE vs SYK Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, SYK has a market cap of 133.6B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while SYK trades at $348.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas SYK's P/E ratio is 26.02. In terms of profitability, NUWE's ROE is -170.16%, compared to SYK's ROE of +0.15%. Regarding short-term risk, NUWE is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check SYK's competition here
Intuitive Surgical, Inc. (NASDAQ: ISRG)
NUWE vs ISRG Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, ISRG has a market cap of 124.7B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while ISRG trades at $352.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas ISRG's P/E ratio is 36.70. In terms of profitability, NUWE's ROE is -170.16%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, NUWE is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check ISRG's competition here
Medtronic plc (NYSE: MDT)
NUWE vs MDT Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, MDT has a market cap of 109.7B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while MDT trades at $85.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas MDT's P/E ratio is 15.50. In terms of profitability, NUWE's ROE is -170.16%, compared to MDT's ROE of +0.10%. Regarding short-term risk, NUWE is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
NUWE vs BSX Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, BSX has a market cap of 68.4B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while BSX trades at $46.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas BSX's P/E ratio is 14.84. In terms of profitability, NUWE's ROE is -170.16%, compared to BSX's ROE of +0.15%. Regarding short-term risk, NUWE is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
NUWE vs EW Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, EW has a market cap of 50.1B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while EW trades at $86.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas EW's P/E ratio is 32.20. In terms of profitability, NUWE's ROE is -170.16%, compared to EW's ROE of +0.10%. Regarding short-term risk, NUWE is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check EW's competition here
ResMed Inc. (NYSE: RMD)
NUWE vs RMD Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, RMD has a market cap of 30.3B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while RMD trades at $208.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas RMD's P/E ratio is 19.37. In terms of profitability, NUWE's ROE is -170.16%, compared to RMD's ROE of +0.24%. Regarding short-term risk, NUWE is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check RMD's competition here
DexCom, Inc. (NASDAQ: DXCM)
NUWE vs DXCM Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, DXCM has a market cap of 28.8B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while DXCM trades at $74.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas DXCM's P/E ratio is 31.99. In terms of profitability, NUWE's ROE is -170.16%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, NUWE is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check DXCM's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
NUWE vs ZBH Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, ZBH has a market cap of 18.4B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while ZBH trades at $94.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas ZBH's P/E ratio is 11.20. In terms of profitability, NUWE's ROE is -170.16%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, NUWE is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
NUWE vs ABMD Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas ABMD's P/E ratio is 65.36. In terms of profitability, NUWE's ROE is -170.16%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, NUWE is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check ABMD's competition here
Smith & Nephew plc (NYSE: SNN)
NUWE vs SNN Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, SNN has a market cap of 13.6B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while SNN trades at $32.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas SNN's P/E ratio is 17.47. In terms of profitability, NUWE's ROE is -170.16%, compared to SNN's ROE of +0.12%. Regarding short-term risk, NUWE is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check SNN's competition here
Penumbra, Inc. (NYSE: PEN)
NUWE vs PEN Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while PEN trades at $319.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas PEN's P/E ratio is 83.54. In terms of profitability, NUWE's ROE is -170.16%, compared to PEN's ROE of +0.12%. Regarding short-term risk, NUWE is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
NUWE vs SWAV Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas SWAV's P/E ratio is 78.76. In terms of profitability, NUWE's ROE is -170.16%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, NUWE is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
NUWE vs ALGN Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while ALGN trades at $173.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas ALGN's P/E ratio is 15.81. In terms of profitability, NUWE's ROE is -170.16%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, NUWE is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check ALGN's competition here
Insulet Corp. (NASDAQ: PODD)
NUWE vs PODD Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, PODD has a market cap of 11.5B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while PODD trades at $165.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas PODD's P/E ratio is 30.80. In terms of profitability, NUWE's ROE is -170.16%, compared to PODD's ROE of +0.21%. Regarding short-term risk, NUWE is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check PODD's competition here
Globus Medical, Inc. (NYSE: GMED)
NUWE vs GMED Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, GMED has a market cap of 10.8B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while GMED trades at $80.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas GMED's P/E ratio is 18.09. In terms of profitability, NUWE's ROE is -170.16%, compared to GMED's ROE of +0.13%. Regarding short-term risk, NUWE is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
NUWE vs GKOS Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, GKOS has a market cap of 9.9B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while GKOS trades at $168.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas GKOS's P/E ratio is -195.91. In terms of profitability, NUWE's ROE is -170.16%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, NUWE is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check GKOS's competition here
Bruker Corporation (NASDAQ: BRKR)
NUWE vs BRKR Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, BRKR has a market cap of 9.8B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while BRKR trades at $64.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas BRKR's P/E ratio is 35.35. In terms of profitability, NUWE's ROE is -170.16%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, NUWE is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check BRKR's competition here
Masimo Corporation (NASDAQ: MASI)
NUWE vs MASI Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas MASI's P/E ratio is 44.43. In terms of profitability, NUWE's ROE is -170.16%, compared to MASI's ROE of +0.09%. Regarding short-term risk, NUWE is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check MASI's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
NUWE vs BIO-B Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, BIO-B has a market cap of 9.3B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while BIO-B trades at $338.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas BIO-B's P/E ratio is 100.27. In terms of profitability, NUWE's ROE is -170.16%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, NUWE is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
NUWE vs BIO Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, BIO has a market cap of 8.8B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while BIO trades at $326.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas BIO's P/E ratio is 35.27. In terms of profitability, NUWE's ROE is -170.16%, compared to BIO's ROE of +0.02%. Regarding short-term risk, NUWE is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check BIO's competition here
Inari Medical, Inc. (NASDAQ: NARI)
NUWE vs NARI Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas NARI's P/E ratio is -59.24. In terms of profitability, NUWE's ROE is -170.16%, compared to NARI's ROE of -0.00%. Regarding short-term risk, NUWE is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
NUWE vs LIVN Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, LIVN has a market cap of 4.5B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while LIVN trades at $81.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas LIVN's P/E ratio is 20.26. In terms of profitability, NUWE's ROE is -170.16%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, NUWE is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
NUWE vs IRTC Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, IRTC has a market cap of 4B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while IRTC trades at $119.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas IRTC's P/E ratio is -218.64. In terms of profitability, NUWE's ROE is -170.16%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, NUWE is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
NUWE vs AXNX Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas AXNX's P/E ratio is -709.80. In terms of profitability, NUWE's ROE is -170.16%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, NUWE is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check AXNX's competition here
Integer Holdings Corporation (NYSE: ITGR)
NUWE vs ITGR Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, ITGR has a market cap of 3.4B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while ITGR trades at $100.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas ITGR's P/E ratio is 15.83. In terms of profitability, NUWE's ROE is -170.16%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, NUWE is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check ITGR's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
NUWE vs ESTA Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, ESTA has a market cap of 2.8B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while ESTA trades at $93.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas ESTA's P/E ratio is -64.92. In terms of profitability, NUWE's ROE is -170.16%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, NUWE is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check ESTA's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
NUWE vs TMDX Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, TMDX has a market cap of 2.6B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while TMDX trades at $76.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas TMDX's P/E ratio is 31.07. In terms of profitability, NUWE's ROE is -170.16%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, NUWE is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
NUWE vs AXGN Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while AXGN trades at $41.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas AXGN's P/E ratio is 108.82. In terms of profitability, NUWE's ROE is -170.16%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, NUWE is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check AXGN's competition here
Butterfly Network, Inc. (NYSE: BFLY)
NUWE vs BFLY Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, BFLY has a market cap of 2.1B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while BFLY trades at $8.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas BFLY's P/E ratio is -34.00. In terms of profitability, NUWE's ROE is -170.16%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, NUWE is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check BFLY's competition here
NuVasive, Inc. (NASDAQ: NUVA)
NUWE vs NUVA Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas NUVA's P/E ratio is 75.00. In terms of profitability, NUWE's ROE is -170.16%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, NUWE is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check NUVA's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
NUWE vs UFPT Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, UFPT has a market cap of 2B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while UFPT trades at $255.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas UFPT's P/E ratio is 26.57. In terms of profitability, NUWE's ROE is -170.16%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, NUWE is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check UFPT's competition here
Novocure Ltd (NASDAQ: NVCR)
NUWE vs NVCR Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while NVCR trades at $15.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas NVCR's P/E ratio is -9.95. In terms of profitability, NUWE's ROE is -170.16%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, NUWE is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check NVCR's competition here
Enovis Corporation (NYSE: ENOV)
NUWE vs ENOV Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, ENOV has a market cap of 1.7B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while ENOV trades at $29.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas ENOV's P/E ratio is 8.67. In terms of profitability, NUWE's ROE is -170.16%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, NUWE is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check ENOV's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
NUWE vs ATEC Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while ATEC trades at $9.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas ATEC's P/E ratio is -87.82. In terms of profitability, NUWE's ROE is -170.16%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, NUWE is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check ATEC's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
NUWE vs AHCO Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, AHCO has a market cap of 1.5B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while AHCO trades at $10.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas AHCO's P/E ratio is 24.27. In terms of profitability, NUWE's ROE is -170.16%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, NUWE is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check AHCO's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
NUWE vs INSP Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, INSP has a market cap of 1.4B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while INSP trades at $50.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas INSP's P/E ratio is 19.41. In terms of profitability, NUWE's ROE is -170.16%, compared to INSP's ROE of +0.18%. Regarding short-term risk, NUWE is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check INSP's competition here
CONMED Corporation (NYSE: CNMD)
NUWE vs CNMD Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while CNMD trades at $46.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas CNMD's P/E ratio is 10.31. In terms of profitability, NUWE's ROE is -170.16%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, NUWE is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check CNMD's competition here
Artivion, Inc. (NYSE: AORT)
NUWE vs AORT Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while AORT trades at $27.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas AORT's P/E ratio is 42.54. In terms of profitability, NUWE's ROE is -170.16%, compared to AORT's ROE of +0.03%. Regarding short-term risk, NUWE is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check AORT's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
NUWE vs IART Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while IART trades at $17.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas IART's P/E ratio is 7.25. In terms of profitability, NUWE's ROE is -170.16%, compared to IART's ROE of -0.01%. Regarding short-term risk, NUWE is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check IART's competition here
Heska Corporation (NASDAQ: HSKA)
NUWE vs HSKA Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas HSKA's P/E ratio is -62.49. In terms of profitability, NUWE's ROE is -170.16%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, NUWE is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check HSKA's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
NUWE vs TNDM Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while TNDM trades at $19.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas TNDM's P/E ratio is -17.28. In terms of profitability, NUWE's ROE is -170.16%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, NUWE is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check TNDM's competition here
IRadimed Corporation (NASDAQ: IRMD)
NUWE vs IRMD Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while IRMD trades at $95.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas IRMD's P/E ratio is 47.37. In terms of profitability, NUWE's ROE is -170.16%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, NUWE is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check IRMD's competition here
Avanos Medical, Inc. (NYSE: AVNS)
NUWE vs AVNS Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas AVNS's P/E ratio is 27.77. In terms of profitability, NUWE's ROE is -170.16%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, NUWE is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check AVNS's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
NUWE vs SILK Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas SILK's P/E ratio is -18.96. In terms of profitability, NUWE's ROE is -170.16%, compared to SILK's ROE of -0.35%. Regarding short-term risk, NUWE is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
NUWE vs FNA Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas FNA's P/E ratio is -19.83. In terms of profitability, NUWE's ROE is -170.16%, compared to FNA's ROE of -0.35%. Regarding short-term risk, NUWE is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check FNA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
NUWE vs PRCT Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, PRCT has a market cap of 1B. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while PRCT trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas PRCT's P/E ratio is -9.89. In terms of profitability, NUWE's ROE is -170.16%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, NUWE is more volatile compared to PRCT. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
NUWE vs LMRI Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, LMRI has a market cap of 984.8M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while LMRI trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas LMRI's P/E ratio is -19.94. In terms of profitability, NUWE's ROE is -170.16%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, NUWE is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check LMRI's competition here
Bioventus Inc. (NASDAQ: BVS)
NUWE vs BVS Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, BVS has a market cap of 892.9M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while BVS trades at $13.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas BVS's P/E ratio is 17.57. In terms of profitability, NUWE's ROE is -170.16%, compared to BVS's ROE of +0.16%. Regarding short-term risk, NUWE is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check BVS's competition here
InMode Ltd. (NASDAQ: INMD)
NUWE vs INMD Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, INMD has a market cap of 867.7M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while INMD trades at $15.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas INMD's P/E ratio is 9.68. In terms of profitability, NUWE's ROE is -170.16%, compared to INMD's ROE of +0.13%. Regarding short-term risk, NUWE is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check INMD's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
NUWE vs CSII Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas CSII's P/E ratio is -20.83. In terms of profitability, NUWE's ROE is -170.16%, compared to CSII's ROE of -0.14%. Regarding short-term risk, NUWE is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check CSII's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
NUWE vs SSII Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, SSII has a market cap of 798.5M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while SSII trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas SSII's P/E ratio is -77.82. In terms of profitability, NUWE's ROE is -170.16%, compared to SSII's ROE of -0.23%. Regarding short-term risk, NUWE is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check SSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
NUWE vs SIBN Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, SIBN has a market cap of 797.8M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while SIBN trades at $17.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas SIBN's P/E ratio is -46.13. In terms of profitability, NUWE's ROE is -170.16%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, NUWE is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check SIBN's competition here
CeriBell, Inc. (NASDAQ: CBLL)
NUWE vs CBLL Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, CBLL has a market cap of 669.3M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while CBLL trades at $17.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas CBLL's P/E ratio is -10.82. In terms of profitability, NUWE's ROE is -170.16%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, NUWE is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check CBLL's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
NUWE vs TCMD Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, TCMD has a market cap of 636.1M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while TCMD trades at $28.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas TCMD's P/E ratio is 32.05. In terms of profitability, NUWE's ROE is -170.16%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, NUWE is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check TCMD's competition here
Surmodics, Inc. (NASDAQ: SRDX)
NUWE vs SRDX Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas SRDX's P/E ratio is -34.66. In terms of profitability, NUWE's ROE is -170.16%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, NUWE is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check SRDX's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
NUWE vs BWAY Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, BWAY has a market cap of 598.2M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while BWAY trades at $15.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas BWAY's P/E ratio is 38.74. In terms of profitability, NUWE's ROE is -170.16%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, NUWE is more volatile compared to BWAY. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check BWAY's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
NUWE vs APEN Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas APEN's P/E ratio is -9.43. In terms of profitability, NUWE's ROE is -170.16%, compared to APEN's ROE of -0.85%. Regarding short-term risk, NUWE is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check APEN's competition here
Cerus Corporation (NASDAQ: CERS)
NUWE vs CERS Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, CERS has a market cap of 579.1M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while CERS trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas CERS's P/E ratio is -57.68. In terms of profitability, NUWE's ROE is -170.16%, compared to CERS's ROE of -0.15%. Regarding short-term risk, NUWE is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check CERS's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
NUWE vs CTKB Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, CTKB has a market cap of 556.6M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while CTKB trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas CTKB's P/E ratio is -33.15. In terms of profitability, NUWE's ROE is -170.16%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, NUWE is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check CTKB's competition here
ZimVie Inc. (NASDAQ: ZIMV)
NUWE vs ZIMV Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, NUWE's ROE is -170.16%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, NUWE is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check ZIMV's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
NUWE vs KIDS Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, KIDS has a market cap of 513.4M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while KIDS trades at $20.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas KIDS's P/E ratio is -19.41. In terms of profitability, NUWE's ROE is -170.16%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, NUWE is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check KIDS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
NUWE vs OFIX Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, OFIX has a market cap of 476.6M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while OFIX trades at $11.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas OFIX's P/E ratio is -48.02. In terms of profitability, NUWE's ROE is -170.16%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, NUWE is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check OFIX's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
NUWE vs NPCE Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, NPCE has a market cap of 468.8M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while NPCE trades at $13.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas NPCE's P/E ratio is -23.71. In terms of profitability, NUWE's ROE is -170.16%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, NUWE is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check NPCE's competition here
Varex Imaging Corporation (NASDAQ: VREX)
NUWE vs VREX Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, VREX has a market cap of 466M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while VREX trades at $11.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas VREX's P/E ratio is 11.65. In terms of profitability, NUWE's ROE is -170.16%, compared to VREX's ROE of -0.18%. Regarding short-term risk, NUWE is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check VREX's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
NUWE vs PACB Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, PACB has a market cap of 459.7M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while PACB trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas PACB's P/E ratio is -3.02. In terms of profitability, NUWE's ROE is -170.16%, compared to PACB's ROE of -4.88%. Regarding short-term risk, NUWE is more volatile compared to PACB. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check PACB's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
NUWE vs CLPT Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, CLPT has a market cap of 437.2M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while CLPT trades at $14.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas CLPT's P/E ratio is -14.44. In terms of profitability, NUWE's ROE is -170.16%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, NUWE is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check CLPT's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
NUWE vs DCTH Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, DCTH has a market cap of 415.6M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while DCTH trades at $12.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas DCTH's P/E ratio is 1204.00. In terms of profitability, NUWE's ROE is -170.16%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, NUWE is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check DCTH's competition here
Carlsmed, Inc. (NASDAQ: CARL)
NUWE vs CARL Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, CARL has a market cap of 344.2M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while CARL trades at $12.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas CARL's P/E ratio is -5.04. In terms of profitability, NUWE's ROE is -170.16%, compared to CARL's ROE of -0.62%. Regarding short-term risk, NUWE is more volatile compared to CARL. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check CARL's competition here
Electromed, Inc. (AMEX: ELMD)
NUWE vs ELMD Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, ELMD has a market cap of 334.9M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while ELMD trades at $40.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas ELMD's P/E ratio is 34.57. In terms of profitability, NUWE's ROE is -170.16%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, NUWE is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check ELMD's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
NUWE vs SMLR Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas SMLR's P/E ratio is 3.92. In terms of profitability, NUWE's ROE is -170.16%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, NUWE is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check SMLR's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
NUWE vs AVR Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, AVR has a market cap of 303.1M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while AVR trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas AVR's P/E ratio is -3.70. In terms of profitability, NUWE's ROE is -170.16%, compared to AVR's ROE of -1.24%. Regarding short-term risk, NUWE is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check AVR's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
NUWE vs SGHT Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, SGHT has a market cap of 286.2M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while SGHT trades at $5.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas SGHT's P/E ratio is -7.41. In terms of profitability, NUWE's ROE is -170.16%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, NUWE is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check SGHT's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
NUWE vs TMCI Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, TMCI has a market cap of 284.1M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while TMCI trades at $4.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas TMCI's P/E ratio is -4.66. In terms of profitability, NUWE's ROE is -170.16%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, NUWE is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check TMCI's competition here
Profound Medical Corp. (NASDAQ: PROF)
NUWE vs PROF Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, PROF has a market cap of 263.4M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while PROF trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas PROF's P/E ratio is -5.85. In terms of profitability, NUWE's ROE is -170.16%, compared to PROF's ROE of -0.70%. Regarding short-term risk, NUWE is more volatile compared to PROF. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
NUWE vs RXST Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, RXST has a market cap of 251.7M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while RXST trades at $6.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas RXST's P/E ratio is -8.44. In terms of profitability, NUWE's ROE is -170.16%, compared to RXST's ROE of -0.17%. Regarding short-term risk, NUWE is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check RXST's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
NUWE vs MGRM Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas MGRM's P/E ratio is -12.00. In terms of profitability, NUWE's ROE is -170.16%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, NUWE is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check MGRM's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
NUWE vs ANIK Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, ANIK has a market cap of 240.4M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while ANIK trades at $18.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas ANIK's P/E ratio is 36.88. In terms of profitability, NUWE's ROE is -170.16%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, NUWE is more volatile compared to ANIK. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check ANIK's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
NUWE vs CATX Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, CATX has a market cap of 231M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while CATX trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas CATX's P/E ratio is -2.12. In terms of profitability, NUWE's ROE is -170.16%, compared to CATX's ROE of -0.42%. Regarding short-term risk, NUWE is more volatile compared to CATX. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check CATX's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
NUWE vs FOCL Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, FOCL has a market cap of 230.1M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while FOCL trades at $6.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas FOCL's P/E ratio is -7.90. In terms of profitability, NUWE's ROE is -170.16%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, NUWE is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check FOCL's competition here
Nevro Corp. (NYSE: NVRO)
NUWE vs NVRO Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas NVRO's P/E ratio is -1.91. In terms of profitability, NUWE's ROE is -170.16%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, NUWE is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check NVRO's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
NUWE vs SENS Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, SENS has a market cap of 211.9M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while SENS trades at $5.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas SENS's P/E ratio is -2.53. In terms of profitability, NUWE's ROE is -170.16%, compared to SENS's ROE of -1.30%. Regarding short-term risk, NUWE is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check SENS's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
NUWE vs BSGM Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas BSGM's P/E ratio is -5.81. In terms of profitability, NUWE's ROE is -170.16%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, NUWE is more volatile compared to BSGM. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
NUWE vs MDGS Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas MDGS's P/E ratio is -0.27. In terms of profitability, NUWE's ROE is -170.16%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, NUWE is more volatile compared to MDGS. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check MDGS's competition here
Inogen, Inc. (NASDAQ: INGN)
NUWE vs INGN Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, INGN has a market cap of 173.8M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while INGN trades at $6.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas INGN's P/E ratio is -7.05. In terms of profitability, NUWE's ROE is -170.16%, compared to INGN's ROE of -0.13%. Regarding short-term risk, NUWE is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check INGN's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
NUWE vs TLSI Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, TLSI has a market cap of 172.9M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while TLSI trades at $4.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas TLSI's P/E ratio is -2.71. In terms of profitability, NUWE's ROE is -170.16%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, NUWE is more volatile compared to TLSI. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check TLSI's competition here
Quanterix Corporation (NASDAQ: QTRX)
NUWE vs QTRX Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, QTRX has a market cap of 165.8M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while QTRX trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas QTRX's P/E ratio is -2.20. In terms of profitability, NUWE's ROE is -170.16%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, NUWE is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check QTRX's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
NUWE vs QIPT Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas QIPT's P/E ratio is -15.87. In terms of profitability, NUWE's ROE is -170.16%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, NUWE is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check QIPT's competition here
CVRx, Inc. (NASDAQ: CVRX)
NUWE vs CVRX Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, CVRX has a market cap of 142.8M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while CVRX trades at $5.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas CVRX's P/E ratio is -2.66. In terms of profitability, NUWE's ROE is -170.16%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, NUWE is more volatile compared to CVRX. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check CVRX's competition here
Picard Medical, Inc. (AMEX: PMI)
NUWE vs PMI Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, PMI has a market cap of 137.1M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while PMI trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas PMI's P/E ratio is -0.07. In terms of profitability, NUWE's ROE is -170.16%, compared to PMI's ROE of +4.99%. Regarding short-term risk, NUWE is more volatile compared to PMI. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check PMI's competition here
Vivani Medical, Inc. (NASDAQ: VANI)
NUWE vs VANI Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, VANI has a market cap of 112.1M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while VANI trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas VANI's P/E ratio is -3.25. In terms of profitability, NUWE's ROE is -170.16%, compared to VANI's ROE of -2.64%. Regarding short-term risk, NUWE is more volatile compared to VANI. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check VANI's competition here
Avita Medical Inc. (NASDAQ: RCEL)
NUWE vs RCEL Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, RCEL has a market cap of 111.5M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while RCEL trades at $4.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas RCEL's P/E ratio is -2.86. In terms of profitability, NUWE's ROE is -170.16%, compared to RCEL's ROE of +3.05%. Regarding short-term risk, NUWE is more volatile compared to RCEL. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check RCEL's competition here
iCAD, Inc. (NASDAQ: ICAD)
NUWE vs ICAD Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas ICAD's P/E ratio is -20.37. In terms of profitability, NUWE's ROE is -170.16%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, NUWE is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check ICAD's competition here
Solana Company (NASDAQ: HSDT)
NUWE vs HSDT Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, HSDT has a market cap of 99.3M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while HSDT trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas HSDT's P/E ratio is -0.02. In terms of profitability, NUWE's ROE is -170.16%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, NUWE is more volatile compared to HSDT. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check HSDT's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
NUWE vs HJLI Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas HJLI's P/E ratio is N/A. In terms of profitability, NUWE's ROE is -170.16%, compared to HJLI's ROE of -0.66%. Regarding short-term risk, NUWE is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check HJLI's competition here
Rapid Micro Biosystems, Inc. (NASDAQ: RPID)
NUWE vs RPID Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, RPID has a market cap of 95.6M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while RPID trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas RPID's P/E ratio is -1.88. In terms of profitability, NUWE's ROE is -170.16%, compared to RPID's ROE of -1.32%. Regarding short-term risk, NUWE is more volatile compared to RPID. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check RPID's competition here
Owlet, Inc. (NYSE: OWLT)
NUWE vs OWLT Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, OWLT has a market cap of 95M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while OWLT trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas OWLT's P/E ratio is -37.50. In terms of profitability, NUWE's ROE is -170.16%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, NUWE is more volatile compared to OWLT. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check OWLT's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
NUWE vs ASXC Comparison July 2026
Nuwellis, Inc. (NASDAQ: NUWE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUWE stands at 1.6M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, NUWE is priced at $4.45 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUWE currently has a P/E ratio of -1.95, whereas ASXC's P/E ratio is -1.12. In terms of profitability, NUWE's ROE is -170.16%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, NUWE is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for NUWE.Check ASXC's competition here